Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Oral Febuxostat in Participants With Gout

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has one or more of the American Rheumatism Association criteria for the diagnosis of gout.~* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.~* Must have a serum urate level greater than or equal to 8.0 milligram per deciliter (mg/dL).~Exclusion Criteria:~* Have a severe, unstable, or life threatening medical condition that would likely prevent them from completing this study.~* Has a known body reaction to febuxostat, allopurinol, naproxen, any other non-steroidal anti-inflammatory drug (NSAID), aspirin, lansoprazole, colchicine, or any components in their formulation.~* History of xanthinuria.~* Alcohol consumption greater than 14/week.~* History of significant concomitant illness.~* Active liver or peptic ulcer disease.~* Has rheumatoid arthritis requiring treatment.~* Has estimated creatinine clearance less than 30 milliliter per minute (mL/min) calculated using the Cockcroft-Gault formula corrected for ideal body weight.~* Requires therapy with any other urate-lowering drug other than the study drug; long-term use of NSAIDs and COX-2 inhibitors; salicylates; thiazide diuretics; losartan; azathioprine; mercaptopurine; theophylline; intravenous (IV) colchicine; cyclosporine; cyclophosphamide; pyrazinamide; sulfamethoxazole;trimethoprim.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Febuxostat 40 mg QD (Type: EXPERIMENTAL): None
- Febuxostat 80 mg QD (Type: EXPERIMENTAL): None
- Allopurinol 200 mg or 300 mg QD (Type: ACTIVE_COMPARATOR): (dependent on renal function)

Based on this trial design, predict the completion outcome and termination type (if applicable).